<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="32666">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02681419</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-12-0800</org_study_id>
    <nct_id>NCT02681419</nct_id>
  </id_info>
  <brief_title>Evaluating the Efficacy of Fenestrations in Tube Shunt Implants During the Early Postoperative Period</brief_title>
  <official_title>Evaluating the Efficacy of Fenestrations in Tube Shunt Implants During the Early Postoperative Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Robert Cizik Eye Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates two different methods of controlling intraocular pressure in nonvalved
      aqueous tube shunts immediately after implantation; needle fenestrations or a suture wick.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized control study of glaucomatous eye undergoing tube shunt
      implantation using a nonvalved implant for poorly controlled glaucoma of any type. Eyes
      scheduled to receive a nonvalved tube shunt implant will be randomized to receive either
      needle fenestration(s) or a suture wick using a single 10-0 vicryl anterior to the ligature.
      The operative quadrant will be imaged using anterior-segment optical coherence tomography at
      pre- and post-operative visits.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with successful control of intraocular pressure</measure>
    <time_frame>3 weeks</time_frame>
    <description>Successful control of intraocular pressure is defined as IOP between 5 and 21 mmHg without medications within 3 weeks postop.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of effect on intraocular pressure control</measure>
    <time_frame>12 weeks</time_frame>
    <description>The duration of effect is defined as elapsed time from surgery to the time that intraocular pressure (IOP) &gt;5 mmHg or &lt;21 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peri-fenestration bleb volume prior to tube opening</measure>
    <time_frame>3 weeks</time_frame>
    <description>Bleb volume will be measured by the anterior segment optical coherence tomography (ASOCT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peri-fenestration bleb volume after the tube has opened</measure>
    <time_frame>12 weeks</time_frame>
    <description>Bleb volume will be measured by the anterior segment optical coherence tomography (ASOCT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure after the tube has opened</measure>
    <time_frame>12 weeks</time_frame>
    <description>Successful control of intraocular pressure is defined as IOP between 5 and 21 mmHg without medications at 12 weeks postop</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Needle fenestration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Needle fenestration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Suture wick</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>suture wick using 10-0 vicryl</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Needle fenestration</intervention_name>
    <description>This technique creates fenestrations along a nonvalved glaucoma implant (e.g. Baerveldt Glaucoma Implant) anterior to the ligature</description>
    <arm_group_label>Needle fenestration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Suture wick</intervention_name>
    <description>This technique places a single 10-vicryl suture wick through the nonvalved glaucoma implant (e.g. Baerveldt Glaucoma Implant) anterior to the ligature</description>
    <arm_group_label>Suture wick</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  Eyes that have poorly controlled glaucoma requiring a tube shunt implantation

          -  Willingness to participate in the study and sign informed consent

        Exclusion Criteria:

          -  Concurrent surgery except phaco/intraocular lens

          -  Any abnormality preventing reliable applanation tonometry

          -  Eyes with exposure limitation (tight lids, deep orbits) that would make performing
             the anterior segment optical coherence tomography difficult
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lauren S. Blieden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Robert Cizik Eye Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lauren S Blieden, MD</last_name>
    <phone>713-559-5200</phone>
    <email>lblieden@cizikeye.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Baker, BS</last_name>
    <phone>713-559-5200</phone>
    <email>laurabaker@cizikeye.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Robert Cizik Eye Clinic</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Baker, B.S.</last_name>
      <phone>713-559-5200</phone>
      <email>laurabaker@cizikeye.org</email>
    </contact>
    <contact_backup>
      <last_name>Theodore Baker</last_name>
      <phone>(713) 559-5200</phone>
      <email>tedbaker@cizikeye.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 4, 2016</lastchanged_date>
  <firstreceived_date>February 9, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Lauren S Blieden</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
